论文部分内容阅读
Epirubicin单药治疗晚期乳腺癌,按照用过化疗与未用过化疗的病人分为两组。两组病人均按每次剂量递增的方法,50mg/M~2,60mg/M~2,70mg/M~2～80mg/M~2静脉注射,每3周1次。结果,未曾化疗的病人达PR的4/9例(44.4％),MR3/9(33.3％),NC2/9(22％)。曾用化疗的病人达CR1/11例(9％),MR2/11例(18％),NC1例,PD7例。Epi-Dx的心肌毒性与骨髓毒性较低,无1例发生急性充血性心力衰竭。本实验表明未曾化疗的病人比曾经化疗的病人疗效较高。
Epirubicin monotherapy for advanced breast cancer was divided into two groups according to patients who used chemotherapy and who had not used chemotherapy. Both groups of patients were given an intravenous dose of 50 mg/M~2, 60 mg/M~2, 70 mg/M~2~80 mg/M~2, every 3 weeks. As a result, 4 of 9 patients (44.4%) had PR without chemotherapy, MR3/9 (33.3%), and NC2/9 (22%). Patients who had been treated with chemotherapy had CR1/11 (9%), MR2/11 (18%), NC1, and PD7. Epi-Dx had lower myocardial toxicity and bone marrow toxicity, and none of the patients developed acute congestive heart failure. This experiment shows that patients who have not been treated with chemotherapy have higher efficacy than patients who have received chemotherapy.